For comparison, we also tested the BRAFV600E-mutant A2058 melanoma cell line and the MDA-MB-468 breast adenocarcinoma cell line, which are reported to be insensitive and sensitive to SHP2 inhibition, respectively47, and which accordingly exhibit differential dependence on PTPN11 gene suppression (Supplementary Fig. 10). This evidence concerns the gene PTPN11 and breast adenocarcinoma.